Erectile Dysfunction Drugs Market Segmentation By Therapeutics (Existing drugs and Pipeline drugs); By Mode of Administration (Injections, Oral Medications and Topical Medications); By Distribution Channel (Online Pharmacies, Retail Pharmacies and Hospital Pharmacies) - Global Demand Analysis & Opportunity Outlook 2027
Buy Now Report ID: 1117 | Published Date: Feb 07, 2023
Our in-depth analysis segmented the global erectile dysfunction drugs market in the following segments:
By Therapeutics:
By Mode of Administration:
By Distribution Channel:
By Region:
The global erectile dysfunction drugs market is further classified on the basis of region as follows:
Get more information on this report: Download Sample PDF
The global erectile dysfunction drugs market is anticipated to expand at a CAGR around 5.0% during 2017-2027. The global erectile dysfunction drugs market is anticipated to value at significant market size during the forecast period. The rising awareness regarding the disease and growing geriatric population is the main reason for the expansion of the erectile dysfunction drugs market.
The global erectile dysfunction drugs market can be segmented on the basis of therapeutics, product type, and distribution channel. On the basis of therapeutics, global erectile dysfunction drugs market is further segmented into existing drugs and pipeline drugs. Existing drugs segment is anticipated to grow at the healthy rate over the forecast period .This is attributed to the fact that existing drugs includes the major drug brands such as Viagra,Cialis, Zydena, Mvix. Based on the mode of administration global erectile dysfunction drugs market is segmented into injections, oral Medications and topical medications
By region, global erectile dysfunction drugs market is segmented into North America, Asia-Pacific, Latin America, Europe, Middle East and Africa. North America is anticipated to be the leading region in the global market of the erectile dysfunction market. The major factor that contributes to the high demand for the erectile dysfunction in the North America is presence of healthcare infrastructure, rising demand for drugs related to dysfunction and increasing R&D related to novel drugs molecules. However, Asia-Pacific region is expected to witness robust growth on the account of rising number of geriatric population, developing drug industry and growing occurrences of erectile dysfunction. The government is also taking various initiatives to boost market of erectile dysfunction.
Various factors that are expected to drive the market growth of erectile dysfunction drugs are the increasing prevalence of the chronic diseases, rising geriatric population and changing lifestyle. Additionally, other factors that are expected to propel the erectile dysfunction drugs market are the increasing geriatric product launches by various companies and enhanced clinical development.
Some of the challenges for the erectile dysfunction drugs market are side effects related to drugs, availability of duplicate drugs, social customs that prohibits many patients to get cured by the drugs.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Submit Your Request For Proposal (RFP)
